Aim To assess the efficacy and safety of PCSK9 antibody AMG145 on lipid-lowering by a meta-analysis. Methods Such database as PubMed, Cochrane Library, EMBase, Web of Science, CNKI, CBM were searched from 2003 to Mar 13, 2015 for randomly collecting case-control clinical trial of AMG145 on lipid-lowering. Assessment and data extraction were conducted by two reviewers independently, meta-analysis was performed by RevMan5.3 software. Results 9 studies involving 2965 patients were included, including 5 Phase 2 and 4 Phase 3 clinical trials, all literatures were published by English. The results of meta-analysis showed that:compared with PBO AMG145 can significantly lower LDLC, Lp(a), ApoB/ApoA1 and elevate HDLC after 12 weeks medication(P＜0.01)； there were no significant differences of total adverse events, myodynia, nasopharyngitis, injection sites reaction, headache and ALT/AST≥3 times ULN between AMG145 and PBO(P＞0.05). Conclusion AMG145 can lower lipid effectively and safely.